Terufumi Kawamoto

Dr. Terufumi Kawamoto

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
TKTerufumi Kawamoto
Terufumi Kawamoto
NSNaoto Shikama
Naoto Shikama
KSKeisuke Sasai
Keisuke Sasai

28 November 2017 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TKTerufumi Kawamoto
Terufumi Kawamoto
KNKeiji Nihei
Keiji Nihei
KSKeisuke Sasai
Keisuke Sasai
KKKatsuyuki Karasawa
Katsuyuki Karasawa
The therapeutic strategies and prognostic risk factors in patients with lymph node (LN) recurrence of esophageal cancer remain controversial. We assessed clinical outcomes and prognostic factors related to the use of chemoradiotherapy (CRT) for LN recurrence of esophageal squamous cell carcinoma (ESCC) after curative resection. We retrospectively evaluated survival and prognostic factors in 57 patients with LN recurrence of ESCC after curative resection. Patients received CRT using 5-fluorouracil plus cisplatin (FP) or docetaxel. Radiotherapy was delivered at 2 Gy (total dose, 60–66 Gy; median, 60 Gy). The median follow-up duration was 24 (range, 3–116) months. The overall survival (OS) rates at 2, 3 and 5 years were 43.7%, 36.9% and 27.6%, respectively. In the univariate analysis of OS, treatment with FP, a single LN recurrence, and a single regional recurrence were associated with a significantly better prognosis (P = 0.04, P = 0.027 and P = 0.0001, respectively). In the multivariate analysis, the combination chemotherapy regimen [hazard ratio (HR), 2.50; 95% confidence interval (CI), 1.23–5.07] and the number of the regional LNs with recurrence (HR, 5.76; 95% CI, 1.22–27.12) were independent prognostic factors. Approximately 28% of ESCC patients with LN recurrence after curative resection could achieve long-term survival with CRT. Treatment with FP or patients with a single regional recurrence might improve the treatment outcome.

1 January 2018 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
KKKatsuyuki Karasawa
Katsuyuki Karasawa
SHSara Hayakawa
Sara Hayakawa
YMYumiko Machitori
Yumiko Machitori
YSYukiko Shibata
Yukiko Shibata
HOHiroaki Ogawa
Hiroaki Ogawa
KNKeiji Nihei
Keiji Nihei
Purpose: Although stereotactic body radiation therapy is one of the standard treatments for stage I nonsmall cell lung cancer, in the case of central tumors it carries the risk of severe adverse events for serial organs. Accelerated hypofractionated radiotherapy is considered a reasonable alternative to treat central tumors. We have been treating central tumors with accelerated hypofractionated radiotherapy using a 75 Gy/25 fr/5 weeks regimen, and we compared the results with those of stereotactic body radiation therapy using 48 Gy/4 fr/1 week. Methods: Patients with central tumors and/or unfit for 1-hour fixation were candidates for accelerated hypofractionated radiotherapy. Based on the proximity to the biologically effective dose at 10 Gy, above accelerated hypofractionated radiotherapy regimen was adopted. Results: From October 2003 to December 2010, 159 patients, who received either accelerated hypofractionated radiotherapy (103 cases) or stereotactic body radiation therapy (56 cases), were included in the analysis. In the accelerated hypofractionated radiotherapy group, 40 (39%) cases were central tumors, whereas all cases were peripheral tumors in the stereotactic body radiation therapy group. Overall 5-year local control and survival rates were 81.9% (95% confidence interval 73.6%-90.1%) and 46.5% (95% confidence interval 36.7%-56.2%), respectively for the accelerated hypofractionated radiotherapy group, and 75.4% (95% confidence interval 63.0%-87.8%) and 44.6% (95% confidence interval 31.6%-57.7%), respectively for the stereotactic body radiation therapy group (n.s.). Among central tumors, ultracentral tumors (21 cases) and the remaining central tumors (19 cases) were similar in both local control and survival. On multivariate analysis, hazard ratios for accelerated hypofractionated radiotherapy versus stereotactic body radiation therapy were <1 for both local control and survival. Pulmonary toxicity was similar in both groups. No serial organ toxicity was observed for central tumors. Conclusions: Accelerated hypofractionated radiotherapy with a 75 Gy/25 fr/5 weeks regimen is promising in that it can obtain similar local control and survival results to stereotactic body radiation therapy, and it can control both central and peripheral tumors without any serial organ toxicities. Based on these results, prospective multicenter trials are worth conducting, especially for ultracentral tumors.

17 July 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
YMYoichi Muramoto
Yoichi Muramoto
NMNaoya Murakami
Naoya Murakami
TKTatsuki Karino
Tatsuki Karino
SSSatoru Sugimoto
Satoru Sugimoto
JTJun Takatsu
Jun Takatsu
NSNaoto Shikama
Naoto Shikama
• MucoUp®, a hyaluronic acid, was used for the first time as a spacer in brachytherapy for uterine cervical cancer. • The study found that MucoUp® can be safely used in gynecologic brachytherapy to create space between CTVHR and OARs, without causing any significant side effects. • MucoUp® insertion enabled the median total CTVHR D90 to exceed 80 Gy while achieving dose constraints of OARs.

1 May 2020 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
TKTerufumi Kawamoto
Terufumi Kawamoto
NSNaoto Shikama
Naoto Shikama
MOMasaki Oshima
Masaki Oshima
YKYasuo Kosugi
Yasuo Kosugi
MTMasahiko Tsurumaru
Masahiko Tsurumaru
KSKeisuke Sasai
Keisuke Sasai

2 September 2020 in Medical Dosimetry
Verified
Journal Article
Closed access
PDF file
TKTerufumi Kawamoto
Terufumi Kawamoto
NSNaoto Shikama
Naoto Shikama
CKChie Kurokawa
Chie Kurokawa
NHNaoya Hara
Naoya Hara
MOMasaki Oshima
Masaki Oshima
KSKeisuke Sasai
Keisuke Sasai